Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680508 · ClinicalTrials.gov registry record · Phase 2
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
A Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by University of Hawaii.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT03680508 is a Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer that is active but no longer recruiting, run by University of Hawaii. The registered enrollment target is 42 participants, above the 24-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (75% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03680508, a Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, is active but no longer recruiting, sponsored by University of Hawaii.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally advanced or metastatic liver cancer.
Conditions Studied
Interventions
- DRUG TSR-022 and TSR-042
Study Locations (2)
Hawaii
- University of Hawaii - Honolulu
Oregon
- Oregon Health & Science University Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680508
The ClinicalTrials.gov registry entry for NCT03680508 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (75% higher). The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which TSR-022 and TSR-042 is the first listed.
NCT03680508 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Hawaii, Oregon.
Frequently Asked Questions
What is clinical trial NCT03680508 about?
NCT03680508 is a clinical study titled "TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer". TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 bind...
What is the current status of trial NCT03680508?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-12-19. Estimated completion is 2027-10.
What conditions does trial NCT03680508 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Adult Primary Liver Cancer.
What interventions are being tested in trial NCT03680508?
The interventions under investigation include: TSR-022 and TSR-042 (DRUG).
Who is sponsoring clinical trial NCT03680508?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680508 being conducted?
This trial has 2 study locations across Hawaii, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
COMPLETED · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
Explore more on PlainTrial
Advanced Adult Primary Liver Cancer
All registered trials for this condition
Localized Unresectable Adult Primary Liver Cancer
All registered trials for this condition
Hawaii
All trials with a study site in Hawaii
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.